This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ETCompany ParticipantsJohn Landry - Chief Financial OfficerOlivier ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business UpdatesAnnounced on August 8, 2025, that the U.S.

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and operating results for the second quarter and ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for Nyxoah (NYXH) and marks the ...

Mont-Saint-Guibert, Belgium– November 28, 2023, 10:30pm CET/ 4:30pm ET– Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to ...

Nyxoah Reports Fourth Quarter and Financial Year 202 4 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025. Revenue ...

Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus ...